Enterprise Value
16.9M
Cash
83.39M
Avg Qtr Burn
-11.84M
Short % of Float
6.72%
Insider Ownership
1.78%
Institutional Own.
41.61%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
UBX1325 (Bcl-xL inhibitor) Details Diabetic macular edema | Phase 2b Initiation | |
UBX1325 (Bcl-xL inhibitor) Details Age-related macular degeneration | Phase 2a Data readout |